Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Complementary Medicine and Therapies
Published in: BMC Complementary Medicine and Therapies 1/2013

Open Access 01-12-2013 | Research article

Kolaviron, a Garcinia biflavonoid complex ameliorates hyperglycemia-mediated hepatic injury in rats via suppression of inflammatory responses

Authors: Omolola R Ayepola, Novel N Chegou, Nicole L Brooks, Oluwafemi O Oguntibeju

Published in: BMC Complementary Medicine and Therapies | Issue 1/2013

Login to get access

Abstract

Background

Chronic inflammation plays a crucial role in hyperglycemia-induced liver injury. Kolaviron (KV), a natural biflavonoid from Garcinia kola seeds have been shown to possess anti- inflammatory properties which has not been explored in diabetes. To our knowledge, this is the first study to investigate the effect of KV on pro-inflammatory proteins in the liver of diabetic rats.

Methods

Diabetes was induced by a single intraperitoneal injection of streptozotocin (STZ) (50 mg/kg) in male Wistar rats. Kolaviron (100 mg/kg) was administered orally five times a week for six weeks. The concentrations of cytokines and chemokine were measured using Bio-plex Pro™ magnetic bead-based assays (Bio-Rad Laboratories, Hercules, USA). Plasma glucose and serum biomarkers of liver dysfunction were analyzed with diagnostic kits in an automated clinical chemistry analyzer. Insulin concentration was estimated by radioimmunoassay (RIA).

Result

Kolaviron (100mg/kg) treatment significantly ameliorated hyperglycemia and liver dysfunction. Serum levels of hepatic marker enzymes were significantly reduced in kolaviron treated diabetic rats. Kolaviron prevented diabetes induced increase in the hepatic levels of proinflammatory cytokines; interleukin (IL)-1beta, IL-6, tumour necrosis factor (TNF-α) and monocyte chemotactic protein (MCP-1).

Conclusion

The results of this study demonstrate that the hepatoprotective effects of kolaviron in diabetic rats may be partly associated with its modulating effect on inflammatory responses.
Appendix
Available only for authorised users
Literature
1.
Yoon J, Jun H: Autoimmune destruction of pancreatic beta cells. Am J Therapeut. 2005, 12 (6): 580-591. 10.1097/01.mjt.0000178767.67857.63.CrossRef
2.
Zanatta L, de Sousa E, Cazarolli LH, Junior AC, Pizzolatti MG, Szpoganicz B, Silva FR, Barreto M: Effect of crude extract and fractions from Vitex megapotamica leaves on hyperglycemia in alloxan-diabetic rats. J Ethnopharmacol. 2007, 109 (1): 151-155. 10.1016/j.jep.2006.07.019.CrossRefPubMed
3.
Lüscher TF, Creager MA, Beckman JA, Cosentino F: Diabetes and vascular disease pathophysiology, clinical consequences, and medical therapy: Part II. Circulation. 2003, 108 (13): 1655-1661. 10.1161/01.CIR.0000089189.70578.E2.CrossRefPubMed
4.
Fisher EB, Thorpe CT, DeVellis BM, DeVellis RF: Healthy coping, negative emotions, and diabetes management, a systematic review and appraisal. Diabetes Educ. 2007, 33 (6): 1080-1103. 10.1177/0145721707309808.CrossRefPubMed
5.
Fowler MJ: Microvascular and macrovascular complications of diabetes. Clin Diabetes. 2008, 26 (2): 77-82. 10.2337/diaclin.26.2.77.CrossRef
6.
Kim JY, Lee SH, Song EH, Park YM, Lim J, Kim DJ, Choi K, Park SI, Gao B, Kim W: A critical role of STAT1 in streptozotocin-induced diabetic liver injury in mice: controlled by ATF3. Cell Signal. 2009, 21 (12): 1758-1767. 10.1016/j.cellsig.2009.07.011.CrossRefPubMedPubMedCentral
7.
Ingaramo PI, Francés DE, Ronco MT, Carnovale CE: Diabetes and Its hepatic complication. Hot topics in endocrine and endocrine-related diseases. Edited by: Fedele M. 2013, InTech, ISBN: 978-953-51-1080-4, doi:10.5772/53684
8.
Harrison SA: Liver disease in patients with diabetes mellitus. J Clin Gastroenterol. 2006, 40 (1): 68-76. 10.1097/01.mcg.0000190774.91875.d2.CrossRefPubMed
9.
10.
Alexandraki KI, Piperi C, Ziakas PD, Apostolopoulos NV, Makrilakis K, Syriou V, Diamanti-Kandarakis E, Kaltsas G, Kalofoutis A: Cytokine secretion in long-standing diabetes mellitus type 1 and 2: associations with low-grade systemic inflammation. J Clin Immunol. 2008, 28 (4): 314-321. 10.1007/s10875-007-9164-1.CrossRefPubMed
11.
Navarro-González JF, Mora-Fernández C: The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol. 2008, 19 (3): 433-442. 10.1681/ASN.2007091048.CrossRefPubMed
12.
Martin-Sanz P, Hortelano S, Callejas NA, Goren N, Casado M, Zeini M, Boscá L: Nitric oxide in liver inflammation and regeneration. Metab Brain Dis. 2002, 17 (4): 325-334. 10.1023/A:1021909902310.CrossRefPubMed
13.
Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, Capeau J, Feve B: Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw. 2006, 17 (1): 4-12.PubMed
14.
Hussain RA, Owegby AG, Parimoo P, Eatomam PG: Kolavonone, a novel polyisoprenylated benzophenone with antimicrobial properties from fruit of Garcinia kola. J Med Plan Res. 1982, 44: 78-81. 10.1055/s-2007-971406.CrossRef
15.
Iwu M, Igboko O: Flavonoids of Garcinia kola seeds. J Nat Prod. 1982, 45 (5): 650-651. 10.1021/np50023a026.CrossRef
16.
Iwu M: Antihepatoxic constituents of Garcinia kola seeds. Experientia. 1985, 41 (5): 699-700. 10.1007/BF02007729.CrossRefPubMed
17.
Abarikwu SO, Farombi EO, Pant AB: Kolaviron biflavanoids of Garcinia Kola seeds protect atrazine-induced cytotoxicity in primary cultures of rat leydig cells. Int J Toxicol. 2012, 31 (4): 407-415. 10.1177/1091581812445476.CrossRefPubMed
18.
Adedara I, Vaithinathan S, Jubendradass R, Mathur P, Farombi E: Kolaviron prevents carbendazim-induced steroidogenic dysfunction and apoptosis in testes of rats. Environ Toxicol Pharmacol. 2013, 35: 444-453. 10.1016/j.etap.2013.01.010.CrossRefPubMed
19.
Farombi EO, Adedara IA, Ajayi BO, Ayepola OR, Egbeme EE: Kolaviron, a natural antioxidant and anti‒inflammatory phytochemical prevents dextran sulphate sodium‒induced colitis in rats. Basic Clin Pharmacol Toxicol. 2013, 113 (1): 49-55. 10.1111/bcpt.12050.CrossRefPubMed
20.
Adedara IA, Farombi EO: Chemoprotection of ethylene glycol monoethyl ether- induced reproductive toxicity in male rats by kolaviron, isolated biflavonoid from Garcinia kola seed. Hum Exp Toxicol. 2012, 31: 506-517. 10.1177/0960327111424301.CrossRefPubMed
21.
Adaramoye O: Antidiabetic effect of kolaviron, a biflavonoid complex isolated from Garcinia kola seeds, in Wistar rats. Afr Health Sci. 2013, 12 (4): 498-506.
22.
Iwu MM, Igboko OA, Okunji CO, Tempesta MS: Antidiabetic and aldose reductase activities of biflavanones of Garcinia kola. J Pharm Pharmacol. 1990, 42 (4): 290-292. 10.1111/j.2042-7158.1990.tb05412.x.CrossRefPubMed
23.
Waterman PG, Hussain RA: Systematic significance of xanthones, benzophenones and biflavonoids in Garcinia. Biochem Syst Ecol. 1983, 11: 21-28. 10.1016/0305-1978(83)90025-X.CrossRef
24.
Wadkar K, Magdum C, Patil S, Naikwade N: Anti-diabetic potential and Indian medicinal plants. J Herb Med Toxicol. 2008, 2 (1): 45-50.
25.
Nwankwo JO, Tahnteng JG, Emerole G: Inhibzition of aflatoxin B1 genotoxicity in human liver-derived HepG2 cells by kolaviron biflavonoids and molecular mechanisms of action. Eur J Cancer Prev. 2000, 9: 351-361. 10.1097/00008469-200010000-00010.CrossRefPubMed
26.
Ahrens B: Antibodies in metabolic diseases. New Biotechnol. 2011, 28 (5): 530-537. 10.1016/j.nbt.2011.03.022.CrossRef
27.
Li Y, Zhang Y, Liu D, Liu H, Hou W, Dong Y: Curcumin attenuates diabetic neuropathic pain by downregulating TNF-α in a rat model. Int J Med Sci. 2013, 10 (4): 377-10.7150/ijms.5224.CrossRefPubMedPubMedCentral
28.
Pan Y, Zhu G, Wang Y, Cai L, Cai Y, Hu J, Li Y, Yan Y, Wang Z, Li X: Attenuation of high-glucose-induced inflammatory response by a novel curcumin derivative B06 contributes to its protection from diabetic pathogenic changes in rat kidney and heart. J Nutr Biochem. 2012, 24: 146-155.CrossRefPubMed
29.
Chang C, Chang C, Huang J, Hung L: Effect of resveratrol on oxidative and inflammatory stress in liver and spleen of streptozotocin-induced type 1 diabetic rats. Chin J Physiol. 2012, 55 (3): 192-201. 10.4077/CJP.2012.BAA012.CrossRefPubMed
30.
Rajesh M, Mukhopadhyay P, Bátkai S, Patel V, Saito K, Matsumoto S, Kashiwaya Y, Horváth B, Mukhopadhyay B, Becker L: Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy. J Am Coll Cardiol. 2010, 56 (25): 2115-2125. 10.1016/j.jacc.2010.07.033.CrossRefPubMedPubMedCentral
31.
Navarro-González JF, Mora-Fernández C, de Fuentes MM, García-Pérez J: Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol. 2011, 7 (6): 327-340. 10.1038/nrneph.2011.51.CrossRefPubMed
32.
Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. New Engl J Med. 2005, 353: 2643-CrossRefPubMed
33.
Bash LD, Selvin E, Steffes M, Coresh J, Astor BC: Poor glycemic control in diabetes and the risk of incident chronic kidney disease even in the absence of albuminuria and retinopathy: Atherosclerosis Risk in Communities (ARIC) Study. Arch Intern Med. 2008, 168 (22): 2440-10.1001/archinte.168.22.2440.CrossRefPubMedPubMedCentral
34.
Adaramoye O, Adeyemi E: Hypoglycaemic and hypolipidaemic effects of fractions from kolaviron, a biflavonoid complex from Garcinia Kola in streptozotocin‒induced diabetes mellitus rats. J Pharm Pharmacol. 2006, 58 (1): 121-128. 10.1211/jpp.58.1.0015.CrossRefPubMed
35.
Mezei O, Banz WJ, Steger RW, Peluso MR, Winters TA, Shay N: Soy isoflavones exert antidiabetic and hypolipidemic effects through the PPAR pathways in obese zucker rats and murine RAW 264.7 cells. J Nutr. 2003, 133 (5): 1238-1243.PubMed
36.
Pinent M, Blay M, Bladé MC, Salvadó MJ, Arola L: Grape seed-derived procyanidins have an antihyperglycemic effect in streptozotocin-induced diabetic rats and insulinomimetic activity in insulin-sensitive cell lines. Endocrinology. 2004, 145: 4985-4990. 10.1210/en.2004-0764.CrossRefPubMed
37.
Naik SR, Fliho JMB, Dhuley JN, Deshmukh A: Probable mechanism of hypoglycaemic activity of bassic acid, a natural product isolated from Bumelia sartorum. J Ethnopharmacol. 1999, 33: 37-44.CrossRef
38.
Waltner-Law ME, Wang XL, Law BK, Hall RK, Nawano M, Granner DK: Epigallocatechin gallate, a constituent of green tea, represses hepatic glucose production. J Biol Chem. 2002, 277: 34933-34940. 10.1074/jbc.M204672200.CrossRefPubMed
39.
Sarkhail P, Rahmaipour S, Fadyevatan S, Mohammadirad A, Dehghan G, Amin G: Antidiabetic effect of Phlomis anisodonta: effects on hepatic cells lipid peroxidation and antioxidant enzymes in experimental diabetes. Pharmacol Res. 2007, 56: 261-266. 10.1016/j.phrs.2007.07.003.CrossRefPubMed
40.
Murray AJ, Anderson RE, Watson GC, Radda GK, Clarke K: Uncoupling proteins in human heart. Lancet. 2004, 364 (9447): 1786-1788. 10.1016/S0140-6736(04)17402-3.CrossRefPubMed
41.
Ravi K, Ramachandran B, Subramanian S: Protective effect of Eugenia jambolana seed kernel on tissue antioxidants in streptozotocin-induced diabetic rats. Biol Pharm Bull. 2004, 27 (8): 1212-1217. 10.1248/bpb.27.1212.CrossRefPubMed
42.
Rawi M, Mourad M, Sayed A: Biochemical and changes in experimental diabetes before and after treatment with Mangifera indica Psidium guava extracts. Int J Pharm Bio Sci. 2011, 2 (2): 29-41.
43.
Li X: Protective effect of Lycium barbarum polysaccharides on streptozotocin-induced oxidative stress in rats. Int J Biol Macromol. 2007, 40 (5): 461-465. 10.1016/j.ijbiomac.2006.11.002.CrossRefPubMed
44.
Soetikno V, Sari FR, Veeraveedu PT, Thandavarayan RA, Harima M, Sukumaran V, Lakshmanan AP, Suzuki K, Kawachi H, Watanabe K: Curcumin ameliorates macrophage infiltration by inhibiting NF-B activation and proinflammatory cytokines in streptozotocin induced-diabetic nephropathy. Nutr Metabol. 2011, 8 (1): 35-10.1186/1743-7075-8-35.CrossRef
45.
Banki E, Degrell P, Kiss P, Kovacs K, Kemeny A, Csanaky K, Duh A, Nagy D, Toth G, Tamas A: Effect of PACAP treatment on kidney morphology and cytokine expression in rat diabetic nephropathy. Peptides. 2013, 42: 125-130.CrossRefPubMed
46.
Wu C, Chen J, Lu K, Chen C, Lin S, Chu P, Sytwu H, Lin Y: Aberrant cytokines/chemokines production correlate with proteinuria in patients with overt diabetic nephropathy. Clin Chim Acta. 2010, 411 (9): 700-704.CrossRefPubMed
47.
Aggarwal BB: Targeting inflammation-induced obesity and metabolic diseases by curcumin and other nutraceuticals. Annu Rev Nutr. 2010, 30: 173-179. 10.1146/annurev.nutr.012809.104755.CrossRefPubMedPubMedCentral
48.
Jain SK, Rains J, Croad J, Larson B, Jones K: Curcumin supplementation lowers TNF-α, IL-6, IL-8, and MCP-1 secretion in high glucose-treated cultured monocytes and blood levels of TNF-α, IL-6, MCP-1, glucose, and glycosylated hemoglobin in diabetic rats. Antioxid Redox Signal. 2009, 11 (2): 241-249. 10.1089/ars.2008.2140.CrossRefPubMedPubMedCentral
49.
Viedt C, Orth SR: Monocyte chemoattractant protein-1 (MCP‒1) in the kidney: does it more than simply attract monocytes?. Nephrol Dial Transplant. 2002, 17 (12): 2043-2047. 10.1093/ndt/17.12.2043.CrossRefPubMed
50.
Tesch GH: MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy. Am J Physiol Ren Physiol. 2008, 294 (4): F697-F701. 10.1152/ajprenal.00016.2008.CrossRef
51.
Tous M, Ferré N, Rull A, Marsillach J, Coll B, Alonso-Villaverde C, Camps J, Joven J: Dietary cholesterol and differential monocyte chemoattractant protein-1 gene expression in aorta and liver of apo E-deficient mice. Biochem Biophys Res Commun. 2006, 340 (4): 1078-1084. 10.1016/j.bbrc.2005.12.109.CrossRefPubMed
52.
Tamura Y, Sugimoto M, Murayama T, Ueda Y, Kanamori H, Ono K, Ariyasu H, Akamizu T, Kita T, Yokode M: Inhibition of CCR2 ameliorates insulin resistance and hepatic steatosis in db/db mice. Arterioscler Thromb Vasc Biol. 2008, 28 (12): 2195-2201. 10.1161/ATVBAHA.108.168633.CrossRefPubMed
53.
Tilg H, Diehl AM: Cytokines in alcoholic and nonalcoholic steatohepatitis. New Engl J Med. 2000, 343: 1467-1476. 10.1056/NEJM200011163432007.CrossRefPubMed
54.
Solt LA, Madge LA, Orange JS, May MJ: Interleukin-1-induced NF-κB activation is NEMO-dependent but does not require IKKβ. J Biol Chem. 2007, 282 (12): 8724-8733. 10.1074/jbc.M609613200.CrossRefPubMedPubMedCentral
55.
Ingaramo PI, Ronco MT, Francés DE, Monti JA, Pisani GB, Ceballos MP, Galleano M, Carrillo MC, Carnovale CE: Tumor necrosis factor alpha pathways develops liver apoptosis in type 1 diabetes mellitus. Mol Immunol. 2011, 48 (12): 1397-1407.CrossRefPubMed
56.
Gui D, Huang J, Guo Y, Chen J, Chen Y, Xiao W, Liu X, Wang N: Astragaloside IV ameliorates renal injury in streptozotocin-induced diabetic rats through inhibiting NF-κB- mediated inflammatory genes expression. Cytokine. 2013, 61: 970-977. 10.1016/j.cyto.2013.01.008.CrossRefPubMed
57.
Cnop M, Welsh N, Jonas J, Jörns A, Lenzen S, Eizirik DL: Mechanisms of pancreatic β- Cell death in type 1 and type 2 diabetes, many differences, few Similarities. Diabetes. 2005, 54 (suppl 2): S97-S107.CrossRefPubMed
58.
Ehses J, Lacraz G, Giroix M, Schmidlin F, Coulaud J, Kassis N, Irminger J, Kergoat M, Portha B, Homo-Delarche F: IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat. Proc Natl Acad Sci. 2009, 106 (33): 13998-14003. 10.1073/pnas.0810087106.CrossRefPubMedPubMedCentral
59.
Ding W, Yin X: Dissection of the multiple mechanisms of TNF‒α‒induced apoptosis in liver injury. J Cell Mol Med. 2004, 8 (4): 445-454. 10.1111/j.1582-4934.2004.tb00469.x.CrossRefPubMed
60.
Olaleye S, Onasanwo S, Ige A, Wu K, Cho C: Anti-inflammatory activities ofa kolaviron- inhibition of nitric oxide, prostaglandin E2 and tumor necrosis factor-alpha production in activated macrophage-like cell line. Afr J Med Med Sci. 2010, 39: 41-46.PubMed
61.
Farombi EO, Shrotriya S, Surh Y: Kolaviron inhibits dimethyl nitrosamine-induced liver injury by suppressing COX-2 and iNOS expression via NF-κB and AP-1. Life Sci. 2009, 84 (5–6): 149-155.CrossRefPubMed
Metadata
Title
Kolaviron, a Garcinia biflavonoid complex ameliorates hyperglycemia-mediated hepatic injury in rats via suppression of inflammatory responses
Authors
Omolola R Ayepola
Novel N Chegou
Nicole L Brooks
Oluwafemi O Oguntibeju
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Complementary Medicine and Therapies / Issue 1/2013
Electronic ISSN: 2662-7671
DOI
https://doi.org/10.1186/1472-6882-13-363

Other articles of this Issue 1/2013

BMC Complementary Medicine and Therapies 1/2013 Go to the issue

Research article

In vitro biological assessment of berberis vulgaris and its active constituent, berberine: antioxidants, anti-acetylcholinesterase, anti-diabetic and anticancer effects

Research article

The use of dietary supplements and their association with blood pressure in a large Midwestern cohort

Research article

Gracilaria edulis extract induces apoptosis and inhibits tumor in Ehrlich Ascites tumor cells in vivo

Research article

Calcarea carbonica induces apoptosis in cancer cells in p53-dependent manner via an immuno-modulatory circuit

Research article

Exploring the decision to disclose the use of natural products among outpatients: a mixed-method study

Research article

Vasorelaxant effect of Prunus yedoensis bark